Shylicine™ - Vanessa Biotech, Inc. - Shylicine
Coming Soon
Description: New research and comprehensive resources for patients with microvillus inclusion disease. At Vanessa Biotech we have patented and will soon begin clinical trials of a drug that has been developed to treat MVID – a treatment that will eliminate life-threatening diarrhea by encouraging immature cells in the intestine to grow normally and restore the absorption of fluids and nutrients.
research (8551) drug (627) restore (545) clinical trials (383) nutrients (144) mvid (4) microvillus inclusion disease (3) vanessa research (3) shylicine (3) treatment diarrhea (1)
Vanessa Biotech is a global biomedical company committed to making an impact on healthcare markets that are often overlooked.
The cornerstone of our company is “research”: everyone, from senior scientist to intern, is involved in the research of new ideas, technologies, and markets. Our core area of research is diarrheal diseases such as cholera, and the rare genetic microvillus inclusion disease.
Vanessa Biotech has etched its niche in developing innovative products by commercializing complex ideas with simple solutions. This is done by creating a respectful teamwork environment conducive to open unrestrained dialog and invention.
Shylicine™ - Vanessa Biotech, Inc. - Shylicine
Coming Soon